Compare VLRS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | PHAT |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Mexico | United States |
| Employees | 6901 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.2M | 894.0M |
| IPO Year | N/A | 2019 |
| Metric | VLRS | PHAT |
|---|---|---|
| Price | $7.80 | $9.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.16 | ★ $19.83 |
| AVG Volume (30 Days) | 525.1K | ★ 1.2M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $13.96 | $93.04 |
| Revenue Next Year | $12.62 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $4.17 | $4.25 |
| 52 Week High | $10.80 | $18.31 |
| Indicator | VLRS | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 31.78 |
| Support Level | $6.88 | N/A |
| Resistance Level | $7.92 | $12.83 |
| Average True Range (ATR) | 0.33 | 0.72 |
| MACD | 0.11 | -0.26 |
| Stochastic Oscillator | 92.82 | 2.57 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.